摘要
突发的新冠肺炎疫情全球大流行是一次对生物医学领域研发创新能力的突击考验,多个国家、企业及科研机构纷纷加入疫苗研发的“竞赛”中。然而,简单地将这场疫苗研发突击战定性为竞争抑或合作是不客观的,容易陷入狭隘的输赢论。本文认为,病毒的不确定性以及疫苗研发过程的复杂性特征决定了创新研发新冠肺炎疫苗具有极高的风险,在不同的研发投入动机驱动下,疫苗研发主体将表现出不同的特征。本文以WHO官方公布的参与166项候选疫苗项目的214家研发机构为样本,结合创新理论对疫苗研发“竞赛”的图景进行分析,客观剖析参与研发主体特征、创新动力及与研发模式之间的关系,深入理解微观主体研发投入动力与创新模式,对政府及公共部门进一步支持生物医药产业创新发展提供决策参考。
The emergency of global pandemic Covid-19 is a great challenge for the innovation capability in biomedical field.Many countries,companies and institutions all over the world have joined in the“competition”of vaccine research and development.However,it is not objective to simply characterize this vaccines development as competitive or cooperative.This paper claimed that both the uncertainty of virus and the complexity of R&D process determine the extremely high risks of R&D investment.Driven by different motives of R&D investment,micro-actors will show different characteristics.In this paper,214 research and development institutions participating in 166 candidate vaccine projects officially announced by WHO are taken as samples.This paper describs the prospect of vaccine research and development“competition”based on innovation theory,objectively analyzes the characteristics of participants in research and development,innovation motivation and the relationship with research and development mode,helps to understand the research and development investment motivation and innovation mode of micro subjects,and provides policy-making references for the government and public departments to further support the innovation and development of biomedical industry.
作者
王秀芹
Wang Xiuqin(School of Public Policy and Management,Tsinghua University,Beijing 100084,China)
出处
《中国科技论坛》
CSSCI
北大核心
2021年第2期1-8,共8页
Forum on Science and Technology in China
基金
清华大学自主科研计划“新兴技术发展对社会结构和社会治理的影响及应对”(20205080071)。
关键词
新冠肺炎疫情
疫苗研发
企业规模
创新动力
生物医药
Covid-19
R&D of vaccine
Scale of company
Innovation motivation
Biomedical industry
